ARCHIMED has acquired a majority stake in Xpress Biologics, enhancing its capacity for producing plasmid DNA, a crucial element in gene and cell therapies, furthering growth opportunities in the biotech sector.

Information on the Target

Xpress Biologics, based in Liège, Belgium, is a premier developer specializing in expression systems and manufacturing processes essential for producing plasmid DNA and protein therapeutics. Established in 2014, the company has emerged as a leader in the production of plasmid DNA, which is increasingly recognized as a critical starting material in the burgeoning field of gene and cell-based therapies, as well as in the development of mRNA-based vaccines. This capability positions Xpress Biologics at the forefront of advanced therapy medicinal products that address severe illnesses, including genetic disorders and viral infections such as COVID-19.

With the global plasmid DNA market currently valued at approximately $1.1 billion, projections indicate a robust growth trajectory, anticipated to witness high double-digit growth rates over the next five years. Xpress Biologics is well-positioned to capitalize on this growth potential, significantly contributing to the advancement of gene and cell therapy solutions.

Industry Overview in Belgium

The life sciences sector in Belgium is characterized by a rich ecosystem that encourages innovation and investment, particularly within biopharmaceuticals. The country is home to cutting-edge research institutions and a strong network of biot